You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
"Best Provider" Winner,
2019 Waters Rankings Awards:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Akari Therapeutics prices $17.4M offering
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
Akari Therapeutics PLC priced an underwritten public offering of 3,480,000 American depositary shares at $5 apiece to raise $17.4 million in gross proceeds.
The company also granted underwriters a 30-day option to buy up to an additional 522,000 of the ADSs offered.
Akari plans to use funds raised for general corporate purposes.
The offering is expected to close by Oct. 20 with Cantor Fitzgerald & Co., William Blair & Co. LLC and Canaccord Genuity Inc. acting as joint book-running managers.